share_log

Cantor Fitzgerald Reiterates Overweight on Orchard Therapeutics, Maintains $15 Price Target

Benzinga ·  Jun 27, 2023 08:18

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Orchard Therapeutics (NASDAQ:ORTX) with a Overweight and maintains $15 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment